Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Rating of “Moderate Buy” by Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company.

A number of research analysts recently weighed in on BAYRY shares. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Finally, UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th.

Key Headlines Impacting Bayer Aktiengesellschaft

Here are the key news stories impacting Bayer Aktiengesellschaft this week:

• Positive Sentiment: The U.S. Supreme Court sided with Bayer in the Roundup warning-label case, a decision that may significantly reduce future lawsuit risk and improve the company’s ability to resolve outstanding claims. Bayer wins Supreme Court case making it harder to sue over glyphosate in Monsanto’s Roundup
• Positive Sentiment: Investors are reacting to the possibility that Bayer’s decades-long Roundup legal overhang could become easier to manage, which supports a rerating of the stock. Bayer Gets New Life After Supreme Court’s Roundup Ruling
• Positive Sentiment: Analysts note that Bayer’s shares have surged on unusually heavy volume following the ruling, reflecting strong investor enthusiasm around the legal victory. Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?

Bayer Aktiengesellschaft Trading Up 1.1%

Shares of Bayer Aktiengesellschaft stock opened at $13.30 on Friday. The company’s fifty day simple moving average is $10.97 and its 200-day simple moving average is $11.50. The stock has a market capitalization of $52.27 billion, a PE ratio of -20.78, a P/E/G ratio of 4.27 and a beta of 0.59. Bayer Aktiengesellschaft has a 1-year low of $7.19 and a 1-year high of $14.85. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.05 and a quick ratio of 0.70.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. The company had revenue of $15.73 billion for the quarter, compared to analysts’ expectations of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities analysts anticipate that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.